Menu +

Korlym Logo

Korlym® (mifepristone) 300 mg Tablets available outside the United States through Idis

Korlym is available to patients globally (outside the United States) through Idis, a Managed Access Company.

  • On a named-patient basis patients can be prescribed investigational or approved drugs prior to commercial launch in their respective countries
  • Corcept is partnering with Idis to ensure regulatory compliance and ethical access to Korlym, a treatment option for patients with Cushing’s syndrom

Korlym is a prescription medicine licensed in the United States to treat adult patients with Cushing’s syndrome who have high blood sugar (hyperglycemia) caused by high cortisol levels and have failed surgery or cannot have surgery. Korlym is a competitive antagonist of the glucocorticoid receptor, which is the primary target of excess cortisol.

Licensed healthcare professionals outside the United States should direct all international product inquiries to:

Sean Maduck, Senior Vice President, Commercial
Tel: 1 (650) 688-2819

Indications and Usage

Korlym® (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

Important Limitations of Use

Do not use for the treatment of type 2 diabetes mellitus unrelated to endogenous Cushing's syndrome.

Important Safety Information


Mifepristone is a potent antagonist of progesterone and cortisol via the progesterone and glucocorticoid (GR-II) receptors, respectively. The antiprogestational effects will result in the termination of pregnancy. Pregnancy must therefore be excluded before the initiation of treatment with Korlym and prevented during treatment and for one month after stopping treatment by the use of a non-hormonal medically acceptable method of contraception unless the patient has had a surgical sterilization, in which case no additional contraception is needed. Pregnancy must also be excluded if treatment is interrupted for more than 14 days in females of reproductive potential.

Please see Full Prescribing Information and Medication Guide.

You are now leaving this website. If you would like to continue, click Continue.
Cancel Continue